Kim SU, Chon YE, Seo YS, et al. - This study was undertaken to investigate the chronological trends in hepatocellular carcinoma (HCC) development risk beginning in 2007 when entecavir reimbursement was first started in South Korea. Researchers grouped 2,442 treatment‐naïve patients with chronic hepatitis B receiving entecavir 0.5 mg/day into early (2007–2010), middle (2011–2012), and late (2013–2014) cohorts, according to when the began entecavir. Older age, male gender, liver cirrhosis, and Child‐Pugh class B were independently associated with an increased risk of HCC, but a reduced risk of HCC development was independently associated with higher platelet count, according to a multivariate analysis. Entecavir start time (early vs. middle vs. late cohorts) did not influence the risk of HCC development. Since 2007, the risk of developing HCC among patients taking entecavir in South Korea has been stable. Future evaluations about the carcinogenic roles of non‐viral factors are needed to develop more efficacious HCC surveillance programs.